Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support

Retrospective Analysis of Clinical Outcomes Associated With the Use of Pegfilgrastim On-body Injector in Patients Receiving Chemotherapy Requiring Granulocyte Colony-Stimulating Factor Support

Objectives: Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) used as primary prophylaxis in patients receiving myelosuppressive chemotherapy regimens that have greater than 20% risk of developing febrile neutropenia (FN). Historically, pegfilgrastim has been administered 24 to 72 hou...

Full description

Bibliographic Details
Main Authors: Arnall, J.R (Author), Benfield, M.J (Author), Larck, C. (Author), Moore, D.C (Author), Patel, J. (Author), Rainess, R.A (Author), Rogers, K.M.L (Author)
Format: Article
Language:English
Published: SAGE Publications Ltd 2021
Subjects:
adult
Article
cabazitaxel
cancer chemotherapy
cancer patient
carboplatin
clinical article
clinical outcome
controlled study
cyclophosphamide
docetaxel
doxorubicin
drug use
febrile neutropenia
female
granulocyte colony-stimulating factor
hospitalization
human
incidence
male
medical record review
middle aged
on-body injector
oncology nursing
paclitaxel
patient satisfaction
pegfilgrastim
pertuzumab
prednisone
retrospective study
rituximab
trastuzumab
treatment outcome
vincristine
workflow
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items